{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:56:58Z","timestamp":1790693818118,"version":"4.1.0"},"reference-count":43,"publisher":"Bioscientifica","issue":"9","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Radioiodine therapy of differentiated thyroid cancer is effective and possibly curative in patients with metastatic lesions that retain iodine avidity. However, in clinical practice, iodine avidity in any metastatic site is usually unknown at the point of initial treatment. Avidity prediction could enable more tailored initial radioiodine treatment. This work aimed to establish the best predictive factors for iodine avidity and subsequent treatment response. Thirty-one patients with metastatic or recurrent thyroid cancer sites in which iodine avidity could be assessed by image-based analysis were included. In tissue specimens from primary surgery, immunohistochemical expression of thyroglobulin (Tg), thyroid peroxidase (TPO), sodium-iodide symporter (NIS), and Ki67 and mutational status of BRAF, RAS, and the TERT promoter were analyzed. Biochemical and structural responses were assessed by serum Tg response and radiological evaluation. High-risk histology (widely invasive follicular, tall cell subtype papillary, differentiated high-grade, or poorly differentiated thyroid carcinoma) combined with the expression of TPO, Tg, and cytoplasmic NIS performed well in predicting treatment response and iodine avidity. Approximately half of the variation between patients was explained by those variables, outperforming pT stage and mutational status. TPO and Tg expression were the largest contributors to prediction modeling. Radioiodine treatment response and iodine avidity in thyroid cancer can be predicted from histopathological analysis of the primary tumor. High-risk histology and the expression of TPO, Tg, and NIS were robust and informative predictors. This may be used to adapt treatment strategy in adjuvant and metastatic therapy settings.<\/jats:p>","DOI":"10.1530\/erc-26-0253","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:07:45Z","timestamp":1788876465000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["Predicting radioiodine therapy response in advanced and recurrent thyroid cancer"],"prefix":"10.1530","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4569-5398","authenticated-orcid":true,"given":"Vincenzo","family":"Condello","sequence":"first","affiliation":[{"name":"Department of Oncology-Pathology, Karolinska Institutet 1 , ,","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2060-6415","authenticated-orcid":true,"given":"Myrsini","family":"Strati","sequence":"additional","affiliation":[{"name":"Department of Oncology-Pathology, Karolinska Institutet 1 , ,","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4758-3170","authenticated-orcid":true,"given":"Daniel","family":"Thor","sequence":"additional","affiliation":[{"name":"Department of Oncology-Pathology, Karolinska Institutet 1 , ,","place":["Stockholm, Sweden"]},{"name":"Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital 2 , ,","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4813-3657","authenticated-orcid":true,"given":"Catharina","family":"Larsson","sequence":"additional","affiliation":[{"name":"Department of Oncology-Pathology, Karolinska Institutet 1 , ,","place":["Stockholm, Sweden"]},{"name":"Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital 3 , ,","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-9081","authenticated-orcid":true,"given":"C Christofer","family":"Juhlin","sequence":"additional","affiliation":[{"name":"Department of Oncology-Pathology, Karolinska Institutet 1 , ,","place":["Stockholm, Sweden"]},{"name":"Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital 3 , ,","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7496-9189","authenticated-orcid":true,"given":"Joachim N","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital 2 , ,","place":["Stockholm, Sweden"]},{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet 4 , ,","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2026092909590649000_bib1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2967\/jnumed.124.269091","article-title":"Impact of radioactive iodine treatment on long-term relative survival in patients with papillary and follicular thyroid cancer: a SEER-based study covering histologic subtypes and recurrence risk categories","volume":"66","author":"Weis","year":"2025","journal-title":"J Nucl Med"},{"key":"2026092909590649000_bib2","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1210\/JC.2015-1346","article-title":"Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987\u20132012","volume":"100","author":"Carhill","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092909590649000_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000504961","article-title":"Systematic review of recurrence rate after hemithyroidectomy for low-risk well-differentiated thyroid cancer","volume":"9","author":"Chan","year":"2020","journal-title":"Eur Thyroid J"},{"key":"2026092909590649000_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2213-8587(24)00276-6","article-title":"Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial","volume":"13","author":"Leboulleux","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026092909590649000_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0140-6736(25)00629-4","article-title":"Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial","volume":"406","author":"Mallick","year":"2025","journal-title":"Lancet"},{"key":"2026092909590649000_bib6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association Management Guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"2026092909590649000_bib7","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-21-0046","article-title":"2022 ETA consensus statement: what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?","volume":"11","author":"Pacini","year":"2022","journal-title":"Eur Thyroid J"},{"key":"2026092909590649000_bib8","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1245\/s10434-019-07275-1","article-title":"Risk of recurrence in differentiated thyroid cancer: a population-based comparison of the 7th and 8th editions of the American Joint Committee on cancer staging systems","volume":"26","author":"Gan","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"2026092909590649000_bib9","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092909590649000_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/10507256251396454","article-title":"A systematic review of absorbed doses and response in patients treated with radioiodine for differentiated thyroid cancer","volume":"36","author":"Taprogge","year":"2025","journal-title":"Thyroid"},{"key":"2026092909590649000_bib11","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1210\/clinem\/dgad697","article-title":"Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid cancer","volume":"109","author":"Mu","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092909590649000_bib12","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(13)60109-9","article-title":"Progress in molecular-based management of differentiated thyroid cancer","volume":"381","author":"Xing","year":"2013","journal-title":"Lancet"},{"key":"2026092909590649000_bib13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1089\/thy.2011.0429","article-title":"Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell\u2013derived thyroid carcinoma with negative diagnostic but positive post-therapy 131 I whole-body scans","volume":"22","author":"Sabra","year":"2012","journal-title":"Thyroid"},{"key":"2026092909590649000_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.119.227652","article-title":"The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer","volume":"61","author":"Liu","year":"2020","journal-title":"J Nucl Med"},{"key":"2026092909590649000_bib15","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1210\/jcem.86.11.8048","article-title":"Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake","volume":"86","author":"Castro","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092909590649000_bib16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","journal-title":"N Engl J Med"},{"key":"2026092909590649000_bib17","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","article-title":"A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-mutated differentiated thyroid cancer","volume":"29","author":"Leboulleux","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026092909590649000_bib18","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1210\/jc.2002-021544","article-title":"Immunohistochemical profile of the sodium\/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections","volume":"88","author":"Wapnir","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092909590649000_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/BF03347392","article-title":"Relationship of sodium\/iodide symporter expression with I131 whole body scan uptake between primary and metastatic lymph node papillary thyroid carcinomas","volume":"30","author":"Lee","year":"2007","journal-title":"J Endocrinol Invest"},{"key":"2026092909590649000_bib20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1530\/EC-17-0302","article-title":"NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features","volume":"7","author":"Tavares","year":"2018","journal-title":"Endocr Connections"},{"key":"2026092909590649000_bib21","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-25-0237","article-title":"Assessing the sodium-iodide symporter (NIS) in pediatric differentiated thyroid carcinoma","volume":"15","author":"Alves-Junior","year":"2026","journal-title":"Eur Thyroid J"},{"key":"2026092909590649000_bib22","first-page":"504","article-title":"Comparison of histology and immunohistochemistry with thyroglobulin serum levels and radioiodine uptake in recurrences and metastases of differentiated thyroid carcinomas","volume":"108","author":"Dralle","year":"1985","journal-title":"Acta Endocrinol"},{"key":"2026092909590649000_bib23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF01606882","article-title":"Histology and immunocytochemistry of differentiated thyroid carcinomas do not predict radioiodine uptake: a clinicomorphological study of 62 recurrent or metastatic tumours","volume":"421","author":"B\u00e4tge","year":"1992","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"2026092909590649000_bib24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/BF01655413","article-title":"Histochemical demonstration of thyroxine, triiodothyronine, and thyroglobulin in the primary lesion of thyroid carcinoma, and its predictability for radioiodine uptake by metastatic lesions","volume":"12","author":"Kodama","year":"1988","journal-title":"World J Surg"},{"key":"2026092909590649000_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13044-015-0022-6","article-title":"The value of thyroperoxidase as a prognostic factor for differentiated thyroid cancer \u2013 a long-term follow-up study","volume":"8","author":"Caballero","year":"2015","journal-title":"Thyroid Res"},{"key":"2026092909590649000_bib26","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1054\/bjoc.2001.2015","article-title":"Is there loss or qualitative changes in the expression of thyroid peroxidase protein in thyroid epithelial cancer?","volume":"85","author":"Czarnocka","year":"2001","journal-title":"Br J Cancer"},{"key":"2026092909590649000_bib27","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-23-0099","article-title":"Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up","volume":"12","author":"Nilsson","year":"2023","journal-title":"Eur Thyroid J"},{"key":"2026092909590649000_bib28","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.3390\/cancers13143627","article-title":"Pre-therapeutic measurements of iodine avidity in papillary and poorly differentiated thyroid cancer reveal associations with thyroglobulin expression, histological variants and Ki-67 index","volume":"13","author":"Nilsson","year":"2021","journal-title":"Cancers"},{"key":"2026092909590649000_bib29","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1210\/jc.2013-3842","article-title":"Outcomes in patients with poorly differentiated thyroid carcinoma","volume":"99","author":"Ibrahimpasic","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092909590649000_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jamaoto.2023.4323","article-title":"Molecular alterations and comprehensive clinical management of oncocytic thyroid carcinoma: a review and multidisciplinary 2023 update","volume":"150","author":"Bischoff","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2026092909590649000_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2017.12.027","article-title":"Predictive factors of outcome in poorly differentiated thyroid carcinomas","volume":"92","author":"de la Fouchardi\u00e8re","year":"2018","journal-title":"Eur J Cancer"},{"key":"2026092909590649000_bib32","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s13139-015-0335-3","article-title":"Radioiodine Scan index: a simplified, quantitative treatment response parameter for metastatic thyroid carcinoma","volume":"49","author":"Oh","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"key":"2026092909590649000_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"key":"2026092909590649000_bib34","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41598-023-27684-3","article-title":"Thyroglobulin expression, Ki-67 index, and lymph node ratio in the prognostic assessment of papillary thyroid cancer","volume":"13","author":"Lindfors","year":"2023","journal-title":"Sci Rep"},{"key":"2026092909590649000_bib35","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1210\/jc.2009-0247","article-title":"Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules","volume":"94","author":"Nikiforov","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092909590649000_bib36","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3390\/cancers11101443","article-title":"Clinical routine TERT promoter mutational screening of follicular thyroid tumors of uncertain malignant potential (FT-UMPs): a useful predictor of metastatic disease","volume":"11","author":"Hysek","year":"2019","journal-title":"Cancers"},{"key":"2026092909590649000_bib37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00259-019-04479-1","article-title":"Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade","volume":"47","author":"Verburg","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026092909590649000_bib38","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1530\/ERC-19-0491","article-title":"Redifferentiation of radioiodine-refractory thyroid cancers","volume":"27","author":"Buffet","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"2026092909590649000_bib39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"2026092909590649000_bib40","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1158\/1078-0432.CCR-22-2882","article-title":"Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy","volume":"29","author":"Boucai","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026092909590649000_bib41","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1007\/s00259-022-05820-x","article-title":"The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer","volume":"49","author":"Cao","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026092909590649000_bib42","doi-asserted-by":"crossref","first-page":"e3206","DOI":"10.1210\/clinem\/dgac305","article-title":"Non-iodine-avid disease is highly prevalent in distant metastatic differentiated thyroid cancer with papillary histology","volume":"107","author":"Soe","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026092909590649000_bib43","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41574-026-01271-8","article-title":"From bench to bedside: the evolving role of iodine in thyroid cancer management","volume":"22","author":"Condello","year":"2026","journal-title":"Nat Rev Endocrinol"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0253\/525015\/erc-26-0253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-26-0253\/525015\/erc-26-0253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:59:22Z","timestamp":1790690362000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/9\/e260253\/78169\/Predicting-radioiodine-therapy-response-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-26-0253","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"e260253"}}